Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma.
暂无分享,去创建一个
Herve Avet-Loiseau | D. Smiraglia | A. Chanan-Khan | H. Avet-Loiseau | L. Coignet | Pushpankur Ghoshal | C. Houde | Asher A Chanan-Khan | Pushpankur Ghoshal | Angela Szafranek | Ashley J. Bigelow | Dominic J Smiraglia | Alain J Nganga | Joseph Moran-Giuati | Timothy R Johnson | Ashley J Bigelow | Christiane M Houde | Noreen Ersing | Lionel J Coignet | N. Ersing | A. Nganga | Angela Szafranek | Joseph Moran-Giuati | Timothy Johnson
[1] P. L. Bergsagel,et al. Multiple myeloma: increasing evidence for a multistep transformation process. , 1998, Blood.
[2] M. Guenther,et al. Assembly of the SMRT-histone deacetylase 3 repression complex requires the TCP-1 ring complex. , 2002, Genes & development.
[3] J Barsoum,et al. Tat-mediated delivery of heterologous proteins into cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[4] Yong Bok Park,et al. Activation of human cancer/testis antigen gene, XAGE‐1, in tumor cells is correlated with CpG island hypomethylation , 2005, International journal of cancer.
[5] Wen‐Ming Yang,et al. Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[6] S. Minoguchi,et al. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-Jκ/Su(H) , 1995, Current Biology.
[7] M. Vidriales,et al. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies. , 1996, Molecular medicine today.
[8] Carl O. Pabo,et al. Cellular uptake of the tat protein from human immunodeficiency virus , 1988, Cell.
[9] J. Herman,et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Hutcheon,et al. TAT-mediated protein transduction into human corneal epithelial cells: p15(INK4b) inhibits cell proliferation and stimulates cell migration. , 2004, Investigative ophthalmology & visual science.
[11] S. Schreiber,et al. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. , 1997, Current opinion in chemical biology.
[12] B. Trask,et al. Characterization, chromosomal localization, and the complete 30-kb DNA sequence of the human Jagged2 (JAG2) gene. , 2000, Genomics.
[13] R. Fisher,et al. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. , 2005, Cancer research.
[14] Michael Tovey,et al. Interaction of the nuclear protein CBF1 with the kappaB site of the IL- 6 gene promoter , 1999, Nucleic Acids Res..
[15] T. Richmond,et al. Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.
[16] Brian T Chait,et al. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. , 2002, Molecular cell.
[17] R. Evans,et al. A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.
[18] A. Frankel,et al. Endocytosis and targeting of exogenous HIV‐1 Tat protein. , 1991, The EMBO journal.
[19] Hidenori Nakajima,et al. [A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[20] R A Kyle,et al. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.
[21] J. Wong,et al. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor. , 2006, Molecular endocrinology.
[22] J. D. Vos,et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. , 2001, Blood.
[23] R. Eisenman,et al. Mad-max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3 , 1995, Cell.
[24] H. Asaoku,et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.
[25] B. Klein,et al. Interleukin-6 in human multiple myeloma. , 1995, Blood.
[26] J. D. Vos,et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.
[27] M. Baron,et al. An overview of the Notch signalling pathway. , 2003, Seminars in cell & developmental biology.
[28] Yulia Nefedova,et al. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. , 2004, Blood.
[29] H. Avet-Loiseau,et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. , 2004, Blood.
[30] S. Artavanis-Tsakonas,et al. Notch signaling: cell fate control and signal integration in development. , 1999, Science.
[31] J. Hsieh,et al. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. , 1995, Science.
[32] Michael Grunstein,et al. Histone acetylation and deacetylation in yeast , 2003, Nature Reviews Molecular Cell Biology.
[33] Takashi Nakamura,et al. Nuclear receptor mediated gene regulation through chromatin remodeling and histone modifications. , 2006, Endocrine journal.
[34] B. Klein,et al. Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias , 1992, Cancer.